Beijing Sun-Novo Pharmaceutical Research

Beijing Sun-Novo Pharmaceutical Research

Beijing Sun-Novo Pharmaceutical Research was established in 2009 by Li Qian, who continues to serve as chairman and controlling shareholder. The company functions as a corporate investor that supplies drug development services. Its operations remain confined to China. The firm conducts small-molecule drug development and maintains a strategic co-development relationship with Uni-Bio Science Group on compounds that include Acarbose. Asset-class exposure centers on transactional financial assets and commercial real estate tied to its laboratory and clinical facilities. Geographic reach covers Beijing and Chengdu. Liu Yujing was appointed CEO and legal representative in March 2020 and holds a 4.16 percent direct stake. The firm lists four operational sites: the Changping headquarters, the Fengtai R&D center, the Daxing clinical center, and the Chengdu Bio-town facility. No recent operational events from the last 24 months appear in available records. The firm’s structure ties investment activity directly to its pharmaceutical services business rather than to an external family or institutional mandate.